Biotechnology · Framingham, Massachusetts, United States
n/a
Smart-Money SignalDistribution · 40/100— Insiders are net sellers over 90 days (-$1.8M, 72 sales vs 12 buys)
Revenue$40.9M
Net Income-$23.5M
EPS$-0.43
Price Performance
Historical data including institutional events
Company Profile
B
Benjamin Palleiko
CEO & Executive Director
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients.
KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
